In search for general PCR targets for minimal residual disease (MRD) studies in acute myeloid leukemia (AML), Wilms' tumor gene 1 (WT1) expression was assessed by real-time RT-PCR relative to the control gene ABL in 569 archived samples of AML patients (pts). Pts were analyzed at diagnosis (n ¼ 116) and during follow-up (n ¼ 105, median 4 times, range 2-17). Median follow-up time was 258 days (range 16-1578 days). In 66 pts, the WT1 expression was analyzed in comparison to a second PCR marker or to multiparameter flow cytometry. Quantitative WT1 levels correlated to the clinical course or a second marker in 83-96% of the cases. Prognostic significance of WT1 levels was analyzed at diagnosis and three intervals: (1) days 16-60, (2) days 61-120, and (3) days 121-180 after start of chemotherapy. Higher levels of WT1 expression were associated with shorter overall survival (OS) and event-free survival (EFS) within intervals 2 and 3 but not at diagnosis or interval 1. In addition, within these intervals, WT1/ABL levels p0.4% were associated with improved OS and EFS. An increase of WT1 levels was detected in 16/44 cases, which subsequently relapsed within a median of 38 days (range 8-180 days). In conclusion, quantification of WT1 may be used for MRD studies and for prognostification in AML.
Introduction
Minimal residual disease (MRD) detection is of growing importance for risk stratification and early detection of relapse in acute myeloid leukemia (AML). Recently, molecular monitoring of minimal residual disease was shown to early identify patient groups at high risk of relapse and therefore provide a window for therapeutic intervention. [1] [2] [3] Monitoring of MRD is mostly based on quantitative PCR. Common targets include specific fusion transcripts, for example, AML1-ETO, CBFB-MYH11, PML-RARA, and MLL gene fusions. However, more than 50% of all AML samples lack one of these specific fusion genes. To enroll even more AML patients (pts) into studies that take PCR-based MRD levels into account, it is crucial to identify molecular targets applicable for the majority of pts. The Wilms' tumor gene 1 (WT1) has previously been reported to be such a pan-leukemic marker. 4 The WT1 gene, initially characterized as a tumor suppressor gene, was first identified as a gene responsible for childhood kidney neoplasia. 5 It is located on chromosome 11p13 and encodes a zinc-finger transcription factor influencing the expression of several growth factors and their corresponding receptors. 6, 7 WT1 has been shown to be overexpressed in more than 90% of myeloid leukemia samples. [8] [9] [10] [11] The concrete role of WT1 in hematopoiesis and leukemogenesis still remains unclear. Studies on the oncogenic activity of WT1 have led to conflicting results demonstrating cell proliferation in some and cell growth arrest in others. 10, [12] [13] [14] [15] WT1 is constitutively expressed in CD34 cells and its level of expression is downregulated with further differentiation. [16] [17] [18] It has been shown previously that in healthy stem cell donors and AML pts in complete morphologic remission, WT1 expression was at comparable levels. 4 Further, it was speculated that WT1 overexpression in leukemic samples seems to originate from leukemic blasts rather than merely reflect immature hematopoiesis. 4 The abundant overexpression of WT1 in leukemia creates a very attractive target for quantitative MRD studies in AML, especially in those samples with no specific fusion gene available. Several studies on WT1 as molecular marker for MRD in AML have been published. [19] [20] [21] [22] However, the results concerning its use as follow-up marker during postremission control have been conflicting. While some groups 20, [21] [22] [23] [24] [25] reported good correlation between the clinical course and WT1 levels, others 26, 27 failed to show correlation. The prognostic relevance of high WT1 levels at diagnosis is also discussed controversially. High levels were found either unfavorable 20, 23, 28, 29 or without prognostic relevance. 26, 27 In some reports, karyotypically favorable AML subgroups were associated with either high 19 or with very low 21 levels of WT1 expression. These discrepancies may be due to different patient cohorts, the use of primers covering different parts of the gene, or due to the different PCR protocols for detection and quantification of WT1 resulting in variable sensitivities. A further problem of WT1 assessment is its background expression in normal hematopoiesis. In healthy individuals, expression levels in peripheral blood samples were significantly lower as compared to bone marrow samples. 19 Our primary goal was to demonstrate the prognostic significance of WT1 expression levels during the course of chemotherapy as has already been shown for classical fusion gene transcripts. 1 Secondary goals were the analysis of WT1 levels at initial presentation and the correlation of follow-up samples using WT1 and a second marker in parallel.
In the presented study, the expression of WT1 was analyzed in the bone marrow of AML pts at diagnosis as well as during and after antileukemic therapy using quantitative real-time RT-PCR. AML samples included pts with available follow-up assessments by quantitative RT-PCR for AML1-ETO, CBFB-MYH11, PML-RARA, and AML1-EVI1. In pts without quantifiable fusion genes, MRD was assessed by flow cytometry, or PCR markers like MLL-PTD and FLT3-LM in addition to WT1.
Patients, materials, and methods

Patient samples
Bone marrow samples were referred to our reference laboratory for central AML diagnosis. AML was diagnosed according to the FAB and WHO classification. [30] [31] [32] The patient characteristics of the total cohort are shown in Table 1 . All pts were treated according to the AMLCG92 and AMLCG99 33, 34 trials. The studies adhered to the declaration of Helsinki and were approved by the ethics committees of the participating institutions prior to the initiation of the studies. Each patient provided informed consent. In 116 pts, WT1 levels were quantified at primary diagnosis. The median age of the pts was 52 years (range 18-81). Eight pts were positive for AML1-ETO, eight for CBFB-MYH11, and 11 for PML-RARA. A total of 50 pts had normal karyotypes and 29 pts had other cytogenetic abnormalities. Nine pts had complex aberrant karyotypes. In one patient, no metaphases could be analyzed. On a molecular level, 6/116 pts had a partial tandem duplication of the MLL gene (MLL-PTD) and 18/116 had an FLT3 length mutation (FLT3-LM). In 89/116 pts, follow-up samples were available. Additional follow-up samples from 16 pts were analyzed, but no quantification of WT1 levels at diagnosis could be performed, summing up to a total of 105 pts with follow-up samples. The median number of follow-up samples was 4 per patient (range 2-17). The median follow-up time was 258 days (range 16-1578 days). In addition, WT1 expression levels were analyzed in nine blood and seven bone marrow samples of healthy donors.
Quantification of WT1 expression during follow-up
In order to assess the prognostic relevance of WT1 expression levels on overall survival (OS) and event-free survival (EFS) during and in the early phase after antileukemic therapy, WT1 levels were quantified within three different intervals -interval 1: days 16-60, interval 2: days 61-120; and interval 3: days 121-180. Therefore, we analyzed the effect of a X2 log reduction, a X3 log reduction, a threshold of 0.04 (defined as complete molecular remission), and a threshold of 0.4% (1 log higher than molecular remission). Finally, the WT1 expression levels of each interval were used as a covariate for a Cox regression model. 
Nucleic acid isolation
cDNA synthesis
Random primed cDNA synthesis with the use of Superscript II (Invitrogene, San Diego, CA, USA) was performed from diagnostic samples using 5 ml of mRNA corresponding to approximately 0.8 Â 10 6 cells in a 50 ml reaction. In order to gain higher sensitivity for follow-up samples, 30 ml of mRNA of 5 Â 10 6 cells was reversely transcribed into cDNA.
Real-time RT-PCR
Real-time RT-PCR was performed using the ABI Prism 7900 s (ABI, Branchburg, NJ, USA). In each reaction, 2 ml of cDNA corresponding to 3.2 Â 10 4 cells was amplified. Each reaction contained 11 ml of mastermix (Taqman Universal PCR Master Mix, ABI, Branchburg, NJ, USA), 0.25 mM FAM labeled hybridization probe (WT1: 5 0 6-FAM-ACA CCG TGC GTG TAT TCT GTA TTG GT XT (TIBMolbiol, Berlin, Germany)), 0.5 mM of each primer (WT1-F: F: 5 0 -GAT AAC CAC ACA ACG CCC ATC; WT1-R: 5 0 -CAC ACG TCG CAC ATC CTG AAT (covering exons 6 and 6/7)) 2 ml of cDNA, and 6.1 ml of H 2 O summing up to a final volume of 22 ml. Amplification after initial incubation at 951C for 10 min was performed in a two-step cycle procedure (denaturation 951C, 15 s, ramp rate 201C/s and annealing 631C, 60 s, ramp rate 201C/s) for 40 cycles.
Quantitative analysis of WT1 expression was performed by standard curve analysis. The expression of WT1 was normalized against the expression of the control gene ABL to adjust for variations in RNA and cDNA synthesis. Conditions for ABL amplification were according to Biomed concerted action. 35 The expression ratios are given in 100 Â WT1/ABL. A dilution series of a known concentration of an ABL plasmid was used to create a standard curve. PCR efficiencies of WT1 and ABL were measured at 1.96 and 1.93, respectively.
The PCR conditions and oligonucleotides for the detection and amplification of PML-RARA, AML1-ETO, CBFB-MYH11, MLL-PTD, and FLT3-LM samples have been described elsewhere. 1, 36 The method of MRD detection by multiparameter flow cytometry has been published recently. 37 
Statistical analysis
Statistical analyses of median values and coefficients of correlation were performed using Excel 7.0 for Windows software. The normalized WT1 expression levels were used as a covariate for Cox regression analysis and correlated to OS and EFS by Spearman rank correlation. Results were significant at a level of Po0.05 at both sides. SPSS 12.0 for Windows software package (SPSS, Chicago, IL, USA) was used for statistical analysis. 
WT1 expression in healthy controls
The median expression level of WT1 in normal bone marrow samples was 0.04 (range 0.01-0.1). In all nine analyzed peripheral blood samples, WT1 expression was undetectable (Table 2) . A WT1 level of at least twice the maximum assessed in healthy controls was defined as WT1 overexpression.
Sensitivity of the WT1 assay
Limiting dilution series were performed in four pts. WT1 levels were detectable with a sensitivity of 1:1000 to 1:10 000 cells, depending on the initial expression ratio. Negative WT1 levels in follow-up samples of pts with detectable fusion gene levels occurred in 2/84 PML-RARA (2%), 3/53 CBFB-MYH11 (6%), and in 0/31 AML1-ETO positive samples. Thus, the sensitivity of WT1 was only slightly worse than that of these fusion genes.
WT1 expression levels at primary diagnosis Bone marrow samples of 116 AML pts at primary diagnosis showed a median expression level of 18.2 (range 0.03-132.73). In 114 of 116 AML pts (98%), WT1 expression was at least twice as high as the expression found in healthy controls.
The influence of WT1 expression levels at diagnosis was determined by Cox regression analysis using WT1 at diagnosis as a continuous variable in 116 pts. There was no significant impact on OS (P ¼ 0.361) or EFS (P ¼ 0.288). To further evaluate the prognostic relevance of presenting WT1 levels in a defined subgroup, only those AML with normal karyotype were analyzed for this application. Within this subgroup, Cox regression again revealed no influence of WT1 expression on OS (P ¼ 0.646) or EFS (P ¼ 0.698).
Blast percentage, CD34 expression, FAB subtype, cytogenetics, molecular genetics, and WT1 levels
The blast percentage at diagnosis ranged from 20 to 100% and did not correlate to the initial WT1 expression level (r ¼ 0.34). The percentage of CD34 expression at diagnosis, assessed by FACScan analysis, also did not correlate to the quantitative WT1 levels (r ¼ 0.22). With respect to cytomorphology, highest WT1 levels at diagnosis were assessed in the M4eo and M3 subtypes, whereas lowest levels were observed in the M5 subtype ( Figure 1a and Table 3 ). However, significant differences were observed only in the M4eo subtype (P ¼ 0.008). In addition, with respect to cytogenetic and molecular genetic features, highest levels of WT1 expression were seen at diagnosis in CBFB-MYH11 (P ¼ 0.008) and PML-RARA (not significant) positive cases. Lowest levels were detected in pts with normal karyotype (P ¼ 0.008; Figure 1b and Table 4 ).
Longitudinal follow-up of WT1 levels in AML patients in comparison to additional follow-up markers
In 66 pts, a comparison to at least one additional follow-up marker -either a molecular marker or a leukemia-associated immunophenotype (LAIP) -was performed. In 16 pts, correlation of WT1 levels to more than one marker was performed (eg MLL Table 5 ). In the six MLL-PTD positive pts, WT1 expression levels were correlated to the MLL-PTD levels. In 5/6 (83%,
In 38 pts, WT1 levels were correlated to expression levels of aberrant immunophenotypes by FACScan analysis. Here, in 33/ 38 pts (87%, median 0.994, range 0.221-0.999), WT1 expression and expression of aberrant immunophenotype revealed significant correlation (Table 5 ). In two pts, a relapse was undetectable by FACScan analysis probably due to shift of the LAIP but relapse was detected by increasing levels of WT1.
Correlation of WT1 levels and the clinical course of the disease
In 75 (71%) of the analyzed pts with follow-up samples, a morphological complete remission (CR) was accompanied by a reduction of WT1 levels of at least 1 log as compared to the prior sample. Persistent leukemia with WT1 levels within 1 log of the preceding sample was observed in 22 (21%) cases. A relapse was observed in 44 (42%) cases.
In 4/105 cases (4%), the WT1 expression did not correlate to the clinical course. In two pts, WT1 levels at relapse remained in the range of the prior sample of cytomorphological CR. In the other two pts, a morphological CR did not coincide with a decrease of WT1 levels as compared to the prior sample (Table 6 ). Exemplary longitudinal quantification of WT1 levels is shown in Figure 2a 
Prognostic relevance of WT1 expression during follow-up
The achievement of a X3 log reduction or a complete molecular remission (p0.04) was not associated with improved OS or EFS at any time. Therefore, a X2 log reduction of WT1 levels was associated with significantly improved EFS within intervals 2 and 3. In addition, there was a trend toward improved OS in intervals Table 2 WT1 expression levels in the peripheral blood and bone marrow of healthy controls as compared to AML patients at diagnosis 
Early detection of relapse
Paired samples were available of 33/44 pts analyzed at diagnosis and at relapse and 30/33 (91%) revealed WT1 overexpression in the range of the diagnostic sample at the time of relapse. One patient demonstrated a rather low initial WT1 expression (0.23). However, at relapse, WT1 expression was 4 log higher than at initial presentation (64.12). Additional aberrations on a cytogenetic or molecular level could not be detected. Two pts relapsed without an increase of WT1 expression levels (see above). The median WT1 levels at diagnosis and relapse were 17 (range 0.66-132.7) and 12 (range 0.64-126.7), respectively. Increasing levels of WT1 of at least 1 log in two consecutive samples or less than 1 log in three consecutive samples were detected in 16 pts with a median of 38 days (range 8-180) before overt hematological relapse (Figure 2a-d) . In the remaining 26 pts, an increase of WT1 levels before hematological relapse could not be detected. In these, the median time between the last samples in hematological CR and relapse was 150 days (range 30-817). 
Discussion
In AML, new markers for MRD studies are eagerly awaited. In the presented work, the expression levels of WT1 were measured in a large cohort of AML pts at primary diagnosis and in follow-up samples during and after antileukemic therapy. WT1 levels were then correlated to the clinical course of the disease as well as to the expression level of an aberrant fusion gene or LAIP if available.
Overexpression of WT1 at diagnosis was observed in 98% of the cases. This is in line with data of previous reports. [8] [9] [10] [11] 21 While some groups have shown that high levels of WT1 coincide with worse prognosis, 20, 23, 28, 29 others failed to show any correlation between initial WT1 levels and outcome of the disease at all. 26, 27 These discrepancies may be due to differing methodologies, for example, real-time PCR vs end-point analysis or due to patient selection. Therefore, we analyzed the outcome of a large number of unselected pts. With respect to the morphological, cytogenetical, and molecular subtypes, our pts represent a standard AML cohort. There was no evidence that the level of WT1 at diagnosis was an independent prognostic factor for survival. In support of this finding, those pts with favorable karyotypes (CBFB-MYH11 and PML-RARA) showed highest WT1 level. In addition, the WT1 expression levels of CBFB-MYH11 positive pts were significantly higher and the levels of the normal karyotype group significantly lower as compared to the total cohort. However, larger patient numbers will be necessary to confirm these data.
In healthy controls, WT1 has been shown to be overexpressed in immature hematopoietic cells. 16, 17 However, in the presented work, there was no significant correlation of WT1 levels and the percentage of CD34 expression, suggesting that WT1 represents leukemic blast load rather than CD34 positivity. Supporting this finding, the CD34 expression in the inv(16) and t (15;17) positive AML that demonstrated highest WT1 expression levels was rather low (median 43 and 6%, range 20-71 and 1-25%, respectively). There was also no significant correlation between the percentage of blast infiltration and the level of WT1 expression. Figure 3b , the value of 0.001 stands for zero. It was corrected due to the logarithmic scale.
The most important and controversially discussed issue aims at the potential of WT1 as a universal marker for MRD studies in AML. Contradictory data on correlation of WT1 and fusion transcript levels seem inexplicable. However, most of the previous studies using quantitative PCR techniques [19] [20] [21] 29, 38 did demonstrate significant correlation as opposed to those who did not. 26, 39 In the presented study, follow-up using WT1 and at least one other clonal marker was possible in 66 pts. Significant correlation was demonstrated in the vast majority of cases (483%). Clinically, there was a close correlation of WT1 levels and the course of the disease in 96% of the cases.
Stability of WT1 expression levels from diagnosis to relapse was observed in 91% of pts. Two pts lost the initial WT1 expression at relapse. Another patient showed low WT1 levels at diagnosis but about 4 log higher levels at relapse. Thus, clonal evolution has to be taken into account.
A molecular relapse was detectable in 16/44 pts, with a median of 38 days before clinical manifestation. This suggests that quantitative assessment of WT1 levels allows early detection of pts at high risk of relapse and may provide sufficient time for development of second-line treatment strategies.
Quantitative monitoring of WT1 levels during the course of therapy was performed demonstrating prognostic significance of WT1 levels after start of therapy. A threshold ratio of 0.4 (100 Â WT1/ABL) was identified that defined two prognostically different subgroups. A ratio p0.4 was associated with improved OS and EFS within 2-4 and 4-6 months after start of therapy. A X2 log reduction was associated with improved EFS and a trend toward improved OS within the same intervals. In addition, the prognostic significance of quantitative WT1 levels was proven by Cox regression analysis. Similar results have been reported by Garg et al 25 in a smaller cohort of mixed ALL and AML pts. A major problem associated with WT1 assessment is interindividual sensitivity due to the variable level of overexpression (0.03-132.7) and the normal 'background noise' of pts in molecular remission and in healthy controls. Thus, from a clinical point of view, one may suggest that the higher the initial level of initial WT1 expression, the more solid the achievement of a 'molecular remission' or a X2 log reduction. However, this hypothesis has to be proven with larger patient numbers. Our PCR assay provided a maximal sensitivity of 1:1000 in 25% and 1:10 000 in 75% of cases, which is slightly less sensitive than most fusion gene PCR assays but in the range of multiparameter flow cytometry. A major advantage for sample processing is that viable material is not necessary. For prospective studies, we would propose to monitor WT1 in all cases in which a more sensitive marker is unavailable, for example, normal karyotype AML.
WT1 was detectable at low levels in the bone marrow but undetectable in peripheral blood of healthy controls. This is in line with data from other studies. 4, 19 The perspective of performing postremission control in AML pts with peripheral blood, presuming that detectable levels of WT1 are indicative for relapse, is tempting. However, as all molecular relapses were detected exclusively in bone marrow samples, further studies on probably due to differences in PCR methodologies or assay design resulting in higher sensitivities. Taken together, our data demonstrate in a large cohort of AML pts that (1) WT1 expression revealed good correlation to the clinical course of the disease, (2) WT1 expression revealed good correlation to other follow-up markers that were assessed in parallel, (3) WT1 expression was able to detect pts at high risk of treatment failure in the early phase of therapy, and (4) that quantitative analysis of WT1 as postremission control enables early detection of imminent relapse. Further prospective trials should test WT1 as follow-up marker especially for those AML where other specific markers for PCR-based MRD detection are lacking. Quantification of WT1 in AML M Weisser et al
